STOCK TITAN

Prescience Point Capital Management Calls On MiMedx Group to Immediately Release Preliminary Voting Results of its Annual Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Prescience Point Capital Management, holding approximately 6.7% of MiMedx Group (MDXG), has expressed concerns over the lack of transparency regarding preliminary voting results from the company's recent annual meeting. The firm suspects that a significant number of shares voted against the re-election of directors and executive compensation proposals. Founder Eiad Asbahi urges MiMedx to disclose voting results to confirm shareholder sentiment. The firm believes that discontent among non-affiliated shareholders could prompt management to prioritize broader shareholder interests.

Positive
  • Potential for increased management accountability if shareholder discontent is confirmed.
Negative
  • Significant number of non-affiliated shares reportedly voted against management, indicating a lack of confidence.
  • Delays in releasing preliminary voting results may suggest underlying issues with shareholder trust.

Believes That a Massive Number of Shares Voted Against the Re-Election of Incumbent Directors and Against Approval of Executive Compensation

BATON ROUGE, La., June 7, 2022 /PRNewswire/ -- Prescience Point Capital Management LLC ("Prescience Point"), a research-focused, catalyst-driven investment firm that beneficially owns approximately 6.7% of the outstanding common stock of MiMedx Group, Inc. ("MDXG" or the "Company") (NASDAQ: MDXG), has issued a statement, calling upon the Company to report the preliminary results of its annual meeting of shareholders, held earlier today.

Eiad Asbahi, Founder and Managing Partner of Prescience Point, stated:

"We find it extremely suspect that, while MiMedx stated during the annual meeting proceedings that director nominees Phyllis Gardner and James Bierman were re-elected, the Company has not taken the usual step of promptly releasing the preliminary voting results to all shareholders."

"In the interest of full transparency, we call upon MiMedx to immediately release the preliminary voting results of the annual meeting, so that the public can see whether the Board and management have lost the confidence of the Company's shareholder base."

"We believe MiMedx is delaying the release of the preliminary vote tally because these results will reveal widespread shareholder discontent.  Based on our discussions with shareholders after the annual meeting, we believe the vote tally will show that a majority of the shares held by non-affiliated, non-institutional holders were voted AGAINST the Company's incumbent director nominees, and AGAINST the Company's executive compensation-based "say-on-pay" proposal."

"If, as we believe, the unaffiliated portion of MiMedx's shareholder base is truly unified in its discontent with the status quo, we are hopeful that this will be the catalyst for the Board and management to begin to operate MiMedx in the best interests of ALL shareholders, and put the Company on a more positive and constructive path."

Disclaimer

This material does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person.  In addition, the discussions and opinions in this press release are for general information only and are not intended to provide investment advice.  All statements contained in this press release that are not clearly historical in nature or that necessarily depend on future events are "forward-looking statements," which are not guarantees of future performance or results, and the words "anticipate," "believe," "expect," "potential," "could," "opportunity," "estimate," and similar expressions are generally intended to identify forward-looking statements.  The projected results and statements contained in this press release that are not historical facts are based on current expectations, speak only as of the date of this press release and involve risks that may cause the actual results to be materially different.  Certain information included in this material is based on data obtained from sources considered to be reliable.  No representation is made with respect to the accuracy or completeness of such data, and any analyses provided to assist the recipient of this presentation in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results.  Accordingly, any analyses should also not be viewed as factual and also should not be relied upon as an accurate prediction of future results. All figures are unaudited estimates and subject to revision without notice. Prescience Point disclaims any obligation to update the information herein and reserves the right to change any of its opinions expressed herein at any time as it deems appropriate. Past performance is not indicative of future results.

About Prescience Point Capital Management

Prescience Point Capital Management is a private investment manager that employs forensic investigative techniques to unearth significant mispricing in global markets. It specializes in extensive investigations of difficult-to-analyze public companies in order to uncover significant elements of the business that have been overlooked or ignored by others.

Prescience Point manages private funds on behalf of its clients and principals and takes positions both long and short in support of its research. Prescience Point invests across a broad set of equities that it believes have abnormally large disparities between what their underlying businesses are intrinsically worth and what their securities sell for. The firm was founded by investor Eiad Asbahi in 2009 and is headquartered in Baton Rouge, LA. Prescience Point Capital Management is a registered investment advisor with the State of Louisiana. Follow @PresciencePoint.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/prescience-point-capital-management-calls-on-mimedx-group-to-immediately-release-preliminary-voting-results-of-its-annual-meeting-301563298.html

SOURCE Prescience Point Capital Management

FAQ

What recent concerns did Prescience Point raise about MiMedx Group (MDXG)?

Prescience Point questioned the lack of transparency regarding the preliminary voting results from MiMedx's annual meeting, suspecting significant shareholder discontent.

What percentage of shares does Prescience Point own in MiMedx Group (MDXG)?

Prescience Point Capital Management beneficially owns approximately 6.7% of the outstanding common stock of MiMedx Group.

What did Prescience Point believe about the voting results at MiMedx Group's annual meeting?

They believe that a majority of non-affiliated shares voted against the re-election of incumbent directors and executive compensation proposals.

Who is the founder of Prescience Point Capital Management?

Eiad Asbahi is the founder and managing partner of Prescience Point Capital Management.

What impact could the preliminary voting results have on MiMedx Group (MDXG)?

If confirmed, the results could lead to increased accountability from management and shifts in the company's operational priorities to better align with shareholder interests.

MiMedx Group, Inc

NASDAQ:MDXG

MDXG Rankings

MDXG Latest News

MDXG Stock Data

1.34B
143.03M
2.45%
68.17%
2.4%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States of America
MARIETTA